



## Chantix® (varenicline) – Pause on Distribution

- On June 24, 2021, multiple [media outlets began reporting](#) that Pfizer was suspending distribution of the smoking cessation aid, Chantix (varenicline), due to discovery of impurities that were found in some of the tablets during product testing.
- Pfizer identified nitrosamine impurities in at least a few lots of Chantix, and halted supply “out of an abundance of caution”. Neither the FDA nor Pfizer have yet issued a recall notification.
- Wholesalers are listing Chantix as backordered from the manufacturer with no expected date to resume shipping product.
- [ASHP](#) and [FDA](#) are listing Chantix on their Drug Shortage Lists.
- Chantix is approved for use as an aid to smoking cessation treatment.
- Alternative aids to smoking cessation are available, including generic and non-prescription options (eg, nicotine replacement therapies).
- Generic formulations of varenicline are expected in 2021 but have not yet launched.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.